Alkermes Logo
IE00B56GVS15
A1JKVH
ALKS

Alkermes

Previsioni

Il prezzo obiettivo medio degli analisti è 53,50 € (+30,58%). La mediana è 53,31 € (+30,12%).

Acquista
  16
Mantieni
  10
Vendi
  3

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Alkermes CCO sells 7,576 shares for $373,000 under 10b5-1 plan

    Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes, sold 7,576 shares on Aug. 17, 2026 for a weighted average price of $49.23, netting about $373,000. The sale was executed under a Rule 10b5-1 trading plan adopted May 15, 2026 and reduced his direct holdings to 102,193 shares (≈0.06% ownership). The company reported strong H1 2026 revenue growth and a 12-month stock gain, and analysts remain generally positive on Alkermes. » Altro su finance.yahoo.com


  • Alkermes reports positive Phase‑2 data for narcolepsy drug Alixorexton

    Alkermes published Phase‑2 data from the Vibrance‑1 study in 92 adults with narcolepsy type 1. Once‑daily doses of 4, 6 or 8 mg Alixorexton produced statistically significant improvements in excessive daytime sleepiness; all dose groups achieved mean Maintenance of Wakefulness Test values of at least 20 minutes and Epworth scores of ≤10 at week 6. In the 6‑mg group the weekly cataplexy rate fell versus placebo; the drug was generally well tolerated and no serious adverse events occurred. Based on these results, a global Phase‑3 program (Brilliance Studies) is now under way; Alixorexton has received Breakthrough Therapy and Orphan Drug status in the US for certain indications. » Altro su de.investing.com


  • Alkermes cuts interest margins for senior term loans

    Alkermes has agreed an amendment to its loan agreement that reduces the interest margins on its secured senior term loans. The adjustment lowers the margin on the TLA facility by 0.75 percentage points and on the TLB facility by 0.50 percentage points; TLA has an outstanding amount of USD 745.3m (maturity Feb. 12, 2031), TLB USD 773.1m (maturity Aug. 12, 2031). After the amendment, TLA will bear interest at Term SOFR plus 1.75–2.25% or Alternate Base Rate plus 0.75–1.25% depending on net leverage, and TLB at Term SOFR plus 2.25% or Alternate Base Rate plus 1.25%. The agreement was made with several lenders, including JPMorgan Chase and BofA Securities as arrangers. » Altro su de.investing.com


  • Alkermes cuts full-year forecast despite strong Q2, stock falls premarket

    Alkermes beat expectations in Q2 2026 with adjusted EPS of $0.00 and revenue of $496 million (+27% y/y), but was weighed down by a 2026 revenue forecast of $1.785 billion that missed the analyst consensus. The stock fell about 5.2% premarket to $50.00 as investors took profits after a strong rally year-to-date. Narcolepsy drug LUMRYZ contributed significantly to revenue, but integration costs and the muted outlook clouded sentiment. Piper Sandler raised its price target to $65 and reiterated “Overweight,” but that did not halt the short-term decline. » Altro su de.investing.com


  • Alkermes hits 52-week high of $55.28 after positive trial data

    Alkermes’ stock climbed to a 52-week high of $55.28 and is trading near that level, with a year-to-date return of about 95%. The company reported positive Phase 2 data from the Alixorexton study VIBRANCE-2, prompting several analysts to raise price targets (Needham $54, Mizuho $65), while BofA moved to underperform on valuation concerns (target $38). The stock shows a high gross margin of 87%, but technical indicators like the RSI point to possible overbought conditions. » Altro su de.investing.com

Dati finanziari

Nell'ultimo trimestre, Alkermes ha registrato ricavi pari a 423,88 Mln € e un utile netto di 14,38 Mln €

(EUR) settembre 2026
YoY
Ricavi 423,88 Mln 26,19%
Utile lordo 340,7 Mln 16,71%
Utile netto 14,38 Mln 79,61%
EBITDA 61,31 Mln 33,88%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
7,1 Mld €
Numero di azioni
168,04 Mln
Massimo/minimo a 52 settimane
50,73 € - 24,61 €
Dividendi No
Beta
0,27
Rapporto P/E
15.445,00
Rapporto PEG
-154,67
Rapporto P/B
4,17
Rapporto P/S
4,44

Profilo aziendale

Alkermes plc, una società biofarmaceutica, ricerca, sviluppa e commercializza prodotti farmaceutici per rispondere ai bisogni medici insoddisfatti dei pazienti in diverse aree terapeutiche negli Stati Uniti, in Irlanda e a livello internazionale. I suoi prodotti commercializzati includono ARISTADA, una sospensione iniettabile intramuscolare per il trattamento della schizofrenia; VIVITROL per il trattamento dell'alcolismo e la prevenzione della dipendenza da oppioidi; RISPERDAL CONSTA per il trattamento della schizofrenia e del disturbo bipolare di tipo I; INVEGA SUSTENNA per il trattamento della schizofrenia e del disturbo schizoaffettivo; XEPLION, INVEGA TRINZA e TREVICTA per il trattamento della schizofrenia e del disturbo schizoaffettivo; e VUMERITY per il trattamento delle forme recidivanti della sclerosi multipla negli adulti, inclusa la sindrome clinicamente isolata, le forme recidivanti-remittenti e le forme attive di sclerosi multipla secondaria progressiva. La società sta inoltre sviluppando LYBALVI, un farmaco antipsicotico atipico orale in fase di candidatura per il trattamento di adulti con schizofrenia e disturbo bipolare di tipo I; e nemvaleukin alfa, una proteina di fusione ingegnerizzata per espandere le cellule immunitarie che uccidono i tumori ed evitare l'attivazione delle cellule immunosoppressive. Ha accordi di collaborazione principalmente con Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc e Janssen Pharmaceutica International. Alkermes plc è stata fondata nel 1987 e ha sede a Dublino, in Irlanda.

Nome
Alkermes
CEO
Blair Jackson
Sede centrale Dublin, du
Irlanda
Sito web
Settore
Materiali
Industria
Prodotti chimici
Quotazione in borsa
16/07/1991
Dipendenti 2050

Simboli di borsa

Borsa Simbolo
NASDAQ
ALKS
Frankfurt
8AK.F
SIX
8AK.SW
München
8AK.MU
🍪

Parqet  usa i cookie. Scopri di più